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Abstract
A key function of the Vpu protein of HIV-1 is the targeting of newly-synthesized CD4 for proteasomal degradation. This
function has been proposed to occur by a mechanism that is fundamentally distinct from the cellular ER-associated
degradation (ERAD) pathway. However, using a combination of genetic, biochemical and morphological methodologies, we
find that CD4 degradation induced by Vpu is dependent on a key component of the ERAD machinery, the VCP-UFD1L-NPL4
complex, as well as on SCF
b-TrCP-dependent ubiquitination of the CD4 cytosolic tail on lysine and serine/threonine residues.
When degradation of CD4 is blocked by either inactivation of the VCP-UFD1L-NPL4 complex or prevention of CD4
ubiquitination, Vpu still retains the bulk of CD4 in the ER mainly through transmembrane domain interactions. Addition of a
strong ER export signal from the VSV-G protein overrides this retention. Thus, Vpu exerts two distinct activities in the
process of downregulating CD4: ER retention followed by targeting to late stages of ERAD. The multiple levels at which Vpu
engages these cellular quality control mechanisms underscore the importance of ensuring profound suppression of CD4 to
the life cycle of HIV-1.
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Introduction
Human Immunodeficiency Virus-1 and -2 (HIV-1 and -2), as
well as Simian Immunodeficiency Virus (SIV), selectively target
helper T-lymphocytes and macrophages/monocytes by binding of
their viral envelope protein, Env, to a combination of two cell-
type-specific surface receptors: a type 1 transmembrane protein,
CD4, and a seven-transmembrane chemokine receptor, CXCR4
or CCR5 [1]. An early and lasting effect of infection is the
downregulation of CD4 from the host cell surface [2,3]. Although
it may seem counterproductive for a virus to downregulate its own
co-receptor, this event actually promotes the establishment of a
robust infection. Indeed, CD4 downregulation prevents (i)
superinfection by additional virions [4], (ii) retention of newly-
synthesized Env precursor in the endoplasmic reticulum (ER) [5],
and (iii) interference with the release of progeny virions from the
cell surface [6]. In addition, CD4 downregulation compromises
the ability of T-lymphocytes to become activated in response to
immunogenic peptides bound to MHC class II molecules on the
surface of antigen-presenting cells [7]. These effects all contribute
to propagation of the infection, eventually leading to depletion of
CD4-positive cells and development of acquired immunodeficien-
cy syndrome (AIDS) in untreated individuals.
The most pathogenic of these viruses, HIV-1, devotes two
accessory proteins encoded in its genome, Nef and Vpu, to the task
of suppressing CD4 expression [8,9,10]. Nef is an N-terminally
myristoylated, cytosolically-disposed peripheral membrane protein
encoded in the genomes of most strains of HIV-1, HIV-2 and SIV.
It is expressed early during infection and functions to accelerate
endocytosis of cell surface CD4 by a clathrin/AP-2 pathway
[11,12,13], followed by delivery of the internalized CD4 to the
multivesicular body pathway for eventual degradation in lyso-
somes [14]. Vpu, on the other hand, is a type III integral
membrane protein having a short luminal N-terminal domain (3–
12 amino acids), a single transmembrane span that doubles as an
uncleaved signal peptide (23 amino acids), and a cytosolic C-
terminal domain (47–59 amino acids). Unlike Nef, Vpu is encoded
in the genomes of only HIV-1 and a few SIV strains [15]. Vpu is
expressed at later stages of infection and acts by targeting newly-
synthesized CD4 in the ER for degradation by cytosolic
proteasomes [16,17]. Together, Nef and Vpu ensure profound
and sustained suppression of CD4 expression throughout the HIV-
1 infectious cycle [18,19].
CD4 downregulation by Vpu depends on an interaction
between the cytosolic domains of both proteins [20]. A canonical
DpSGxxpS sequence containing two phosphorylated serine (pS)
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56 in the NL4-3 variant of HIV-1 used in this study) then binds b-
TrCP1 [21] and b-TrCP2 (also known as FBXW11/HOS) [22],
two paralogous F-box adaptor proteins for the cytosolic SCF
b-TrCP
E3 ubiquitin (Ub) ligase complex. Recruitment of this SCF
complex results in ubiquitination of the CD4 cytosolic tail on
lysine residues [23,24], marking CD4 for degradation by cytosolic
proteasomes [17]. Unlike CD4, Vpu itself is not ubiquitinated and
degraded in this process [25]. Vpu function, therefore, can be
likened to that of Ub ligase adaptors, which link substrates to Ub
ligases [26].
At first blush, the process of Vpu-induced CD4 degradation
evokes the well-known ER-associated degradation (ERAD)
pathway, which generally functions to dispose of abnormal
proteins from the ER [27,28,29]. Two sets of observations,
however, distinguish Vpu function from targeting to typical
ERAD. First, the cytosolic SCFb-TrCP complex does not
normally function in ERAD, but is responsible for the ubiquitina-
tion and degradation of non-ERAD substrates such as IkBa and b-
catenin [30,31]. Instead, the ERAD pathway employs several
membrane-bound Ub ligases, including the HRD1-SEL1L
complex [32,33], TEB4/MARCH-VI [34], and the GP78-
RMA1 complex [35,36] (names and references correspond to
the mammalian orthologs). Second, genetic analysis involving
expression of human CD4 and HIV-1 Vpu in the yeast S. cerevisiae,
showed that CD4 degradation in the presence of Vpu is
independent of components of the ERAD machinery such as
Hrd1p, Hrd3p and Ubc7p (yeast names; orthologous to the
mammalian proteins HRD1, SEL1L and UBC7, respectively)
[23]. These observations have led to the notion that the
mechanism by which Vpu induces CD4 degradation is funda-
mentally distinct from ERAD [23].
We have put this notion to the test by examining the
requirement of additional components of the ERAD machinery
for Vpu-induced CD4 degradation in human cells. Using siRNA
and dominant-negative overexpression approaches, we find a
requirement for the VCP-UFD1L-NPL4 complex, which is a key
component of the ERAD machinery [37,38,39,40]. In addition,
we show that degradation depends on ubiquitination of CD4 on
not only lysine, but also serine/threonine residues, the first
instance in which a cellular Ub ligase activity is implicated in
serine/threonine ubiquitination of an ERAD substrate. Inactiva-
tion of the VCP-UFD1L-NPL4 complex prevents degradation of
CD4 induced by Vpu. Under these conditions, CD4 accumulates
in the ER as a properly folded and membrane-associated protein,
indicating that the VCP-UFD1L-NPL4 complex plays a role in the
dislocation of CD4 from the ER membrane. Dissection of the
mechanism by which Vpu retains CD4 in the ER reveals at least
two contributing factors: SCF
b-TrCP-dependent ubiquitination of
the CD4 cytosolic tail and transmembrane domain (TMD)
interactions. These findings indicate that Vpu exerts two distinct,
separable activities in the process of downregulating CD4:
retention in the ER followed by targeting to a variant ERAD
pathway.
Results
Requirement of the VCP-UFD1L-NPL4 Complex for
Vpu-induced CD4 Degradation
To determine whether Vpu-induced degradation of CD4
involves any part of the ERAD pathway, we tested for the
requirement of key components of the ERAD machinery using a
siRNA approach in human cells. To this end, HeLa cells were
treated with siRNAs directed to eighteen proteins that mediate
various ERAD steps (Table S1) [28]. Human CD4 was then co-
expressed with codon-optimized, wild-type HIV-1 Vpu [41] or
inactive HIV-1 Vpu bearing mutations of serines 52 and 56 (Vpu-
S52,56N) [25] by transient transfection. Total levels of CD4 were
determined by immunoblot analysis. A typical immunoblot for
negative and positive siRNA controls is shown in Fig. 1A, and
quantification of the results from three independent experiments
for all the siRNAs tested is shown in Fig. 1B. In cells treated
without (mock) or with siRNAs to an irrelevant protein, GAPDH,
expression of wild-type Vpu lowered total CD4 levels to ,5% of
those in control, non-Vpu- or Vpu-S52,56N-expressing cells
(Fig. 1, A and B). Combined treatment with siRNAs to b-TrCP1
and b-TrCP2 (b-TrCP1/2) largely protected CD4 from Vpu-
induced loss (to ,60% of control cells), in agreement with previous
findings [21,22]. The remaining siRNA treatments had various
effects, with siRNAs to VCP (also known as p97), UFD1L or NPL4
causing the greatest degree of protection (,60% of control cells).
These three cytosolic proteins form a complex that participates in
ERAD by extracting or ‘‘dislocating’’ ubiquitinated substrates
from the ER membrane [37,38,39,40]. These observations thus
pointed to the involvement of at least part of the ERAD pathway
in Vpu-induced CD4 degradation.
Depletion of the VCP-UFD1L-NPL4 Complex Prevents
Vpu-induced CD4 Degradation and Results in
Accumulation of Folded, Membrane-bound CD4
To ascertain that the prevention of CD4 loss by depletion of
VCP, UFD1L or NPL4 was due to a block in CD4 degradation,
we performed pulse-chase analysis (Fig. 1, C–F). Cells treated with
the corresponding siRNAs and transfected with plasmids encoding
CD4, plus or minus Vpu, were labeled for 2 min with
[
35S]methionine-cysteine and chased for different times in
complete medium. Immunoprecipitation with a conformation-
independent antibody showed that expression of Vpu shortened
the half-life of CD4 from ,4.8 h (Fig. S1, A and B) [16] to
,20 min in mock-treated cells (Fig. 1, C and D; Fig. S1, C-F).
Depletion of VCP, UFD1L or NPL4 largely abrogated the rapid
degradation of CD4 induced by Vpu (Fig. 1, C and D; Fig. S1, E
and F). Use of a conformation-dependent antibody revealed
progressive acquisition of a conformational epitope upon folding of
the CD4 ectodomain in the absence of Vpu (Fig. 1, E and F). In
Author Summary
HIV-1 devotes two accessory proteins, Nef and Vpu, to the
task of removing the viral receptor, CD4, from the cell
surface. Whereas Nef delivers surface CD4 for degradation
in lysosomes, Vpu targets newly-made CD4 in the
endoplasmic reticulum for degradation by cytosolic
proteasomes. This latter process was thought to be
fundamentally distinct from that used for the disposal of
abnormal cellular proteins from the endoplasmic reticu-
lum. Contrary to this notion, however, we show that Vpu
utilizes at least part of the endoplasmic reticulum-
associated degradation machinery to dispose of CD4.
Disabling this machinery prevents CD4 degradation
induced by Vpu but, surprisingly, does not allow transport
of CD4 to the cell surface. This is due to a second function
of Vpu: retention of CD4 in the endoplasmic reticulum.
These two functions of Vpu are mediated by different parts
of the Vpu molecule and involve distinct mechanisms. This
functional redundancy underscores the importance of
suppressing CD4 expression for HIV-1 to thrive in the
infected cells.
Mechanism of CD4 Downregulation by Vpu
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the folded CD4 species by counteracting folding with degradation
(Fig. 1, E and F). Inhibition of degradation by depletion of VCP,
UFD1L or NPL4 restored CD4 ectodomain folding (Fig. 1, E and
F). Subcellular fractionation and Na2CO3 treatment showed that
the population of CD4 that was protected from Vpu-induced
degradation by VCP, UFD1L or NPL4 depletion remained
integrally associated with membranes (Fig. 1G). These experi-
ments thus demonstrated that depletion of the VCP-UFD1L-
NPL4 complex prevents degradation of CD4 in the presence of
Vpu. Under these conditions, the CD4 ectodomain continues to
fold while retaining its association with membranes. Moreover,
these findings support the notion that the VCP-UFD1L-NPL4
complex is required for extraction of CD4 from membranes.
The ATPase Activity of VCP is Required for Vpu-induced
CD4 Degradation
VCP is a member of the AAA-ATPase superfamily; it comprises
an N-terminal domain (N) that binds UFD1L and NPL4, and two
AAA-ATPase domains (D1 and D2) (Fig. 2A). To investigate the
requirement of these domains in Vpu-induced CD4 degradation,
we introduced mutations in the VCP cDNA and overexpressed
these mutants together with CD4 and Vpu by transfection into
HeLa cells. The fate of CD4 was then examined by pulse-chase
analysis. VCP-DN is a VCP deletion mutant lacking most of the N
domain (residues 1–185) (Fig. 2A) [39]. We found that
overexpression of this construct had no effect on CD4 degradation
(Fig. 2, B and C), probably because this mutant is unable to
assemble with the ubiquitin-binding UFD1L and NPL4 proteins,
cannot be targeted to ubiquitinated substrates, and does not
compete with endogenous VCP. Mutation of lysine and glutamate
residues in the active sites of both ATPase domains to alanine
(VCP-AA) or glutamine (VCP-QQ) residues, respectively (Fig. 2A),
is known to prevent ATP binding (VCP-AA) or ATP hydrolysis
(VCP-QQ) [39]. Because of the presence of the N domain, these
constructs are capable of assembling with UFD1L and NPL4,
allowing the recruitment of catalytically-inactive VCP to ubiqui-
tinated substrates. The VCP-AA mutant was previously shown to
abrogate Vpu-induced CD4 degradation [24]. We confirmed this
observation and, in addition, found that the VCP-QQ had a
similar effect (Fig. 2, B and C), indicating that these mutants
exerted a potent dominant-negative effect, and that both ATP
binding and hydrolysis are required for this process. VCP is thus
likely to provide the energy required for extraction of CD4 from
membranes. In line with this conclusion, depletion of ATP by
incubation of cells in glucose-free medium supplemented with 2-
deoxy-D-glucose and sodium azide [42] inhibited CD4 degrada-
tion induced by Vpu (Fig. 2, D and E). Co-precipitation
experiments showed that the substrate-trapping VCP-QQ mutant
was isolated as a complex with CD4 in the presence of wild-type
Vpu but not Vpu-S52,56N (Fig. 2F). Because these Vpu constructs
differ in their ability to promote CD4 ubiquitination by the
SCF
b-TrCP complex (Fig. S2), our findings are consistent with
recruitment of VCP to ubiquitinated CD4.
Ub Binding to UFD1L, but not NPL4, is Important for CD4
Degradation by Vpu
The recruitment of VCP to CD4 is likely mediated by UFD1L
and NPL4. These proteins form a heterodimer that assembles with
a VCP homohexamer [43]. Both UFD1L and NPL4 contain
binding sites for each other and for VCP (Fig. 2A) [44,45]. In
addition, UFD1L and NPL4 contain domains that bind K48-
linked and K63-linked Ub chains, respectively (Fig. 2A) [39,46].
Overexpression of an UFD1L mutant lacking the binding site for
VCP and NPL4 (UFD1L-DUT6) had no effect on Vpu-mediated
CD4 degradation (Fig. 2, G and H), probably because it cannot
interfere with the ability of endogenous UFD1L to engage VCP
and NPL4 for interaction with ubiquitinated CD4. Overexpres-
sion of an UFD1L mutant lacking the Ub-binding domain
(UFD1L-DUT3), on the other hand, inhibited Vpu-induced
CD4 degradation (Fig. 2, G and H), whereas overexpression of
an analogous NPL4 mutant (NPL4-DZFD) had no effect on this
process (Fig. 2, I and J). The dominant-negative effect of UFD1L-
DUT3 might be explained by the ability of this mutant to bind
both VCP and NPL4 but not be recruited to proteins conjugated
to K48-linked Ub chains. This is consistent with the specific
involvement of K48 Ub linkages in ERAD [39]. We also observed
that overexpression of a NPL4 mutant lacking the VCP-binding
domain (NPL4-DUBD) failed to elicit a dominant-negative effect
(Fig. 2, I and J). The inability of these NPL4 mutants to exert a
dominant-negative effect stands in sharp contrast with the
inhibitory effect of the NPL4 siRNAs on Vpu-induced CD4
degradation (Fig. 1, B-D). The explanation for this apparent
discrepancy lay on the effects of each siRNA on the levels of the
three components of the complex (Fig. 2K). Indeed, siRNAs to
VCP, UFD1L or NPL4 resulted in depletion of the corresponding
target protein without affecting the levels of the other two, with the
notable exception of the NPL4 siRNAs, which depleted both
NPL4 and UFD1L (Fig. 2K). This indicated that NPL4 is required
to stabilize UFD1L, as previously reported [47]. Taken together,
these findings ascribe specific functions to each of the components
of the VCP-UFD1L-NPL4 complex in Vpu-mediated CD4
degradation: VCP energizes the process through ATP binding
and hydrolysis, UFD1L binds ubiquitinated CD4 through
recognition of K48 Ub chains, and NPL4 stabilizes UFD1L.
Vpu Also Mediates Retention of CD4 in the ER
We next wondered whether inhibition of Vpu-induced CD4
degradation by interference with the VCP-UFD1L-NPL4 complex
allowed transport of newly-synthesized CD4 out of the ER. To
Figure 1. The VCP-UFD1L-NPL4 complex mediates Vpu-dependent CD4 degradation. (A) HeLa cells were treated without (mock) or with
siRNAs to GAPDH (negative control) or b-TrCP1/2 (positive control). Cells were then transfected with plasmids encoding human CD4 and no Vpu
(empty vector), wild-type Vpu or Vpu-S52,56N. At 12 h after transfection, cell lysates were analyzed by SDS-PAGE and immunoblotting with
antibodies to the CD4 ectodomain and actin (used as a loading control). (B) HeLa cells treated with different siRNAs were processed as in A. CD4
levels in the presence of Vpu were quantified by densitometry and expressed as percentage of the total amount of CD4 in the absence of Vpu (100%
control). Values represent the mean 6 SEM from three independent screens. (C, E) HeLa cells were treated as in A with siRNAs to VCP, UFD1L or NPL4,
and then transfected with plasmids encoding human CD4, plus or minus Vpu. At 12 h after transfection, cells were labeled with [
35S]methionine-
cysteine for 2 min and chased for the indicated times at 37uC. Cell extracts were subjected to immunoprecipitation of CD4 using a conformation-
independent (C) or conformation-dependent (E) antibody. Immunoprecipitated proteins were resolved by SDS-PAGE and fluorography. (D, F)
Percentage of CD4 at each chase time relative to CD4 at time 0 (100% control). (G) A postnuclear supernatant of HeLa cells treated as in C and E was
separated into cytosolic and membrane fractions. The membranes were washed with 0.2 M Na2CO3 pH 11.3, and pellet (P) and supernatant (S)
fractions were collected. Fractions were analyzed by SDS-PAGE and immunoblotting with antibodies to the CD4 ectodomain and actin (used as a
cytosolic marker).
doi:10.1371/journal.ppat.1000869.g001
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NPL4 (which, as described above, depleted both NPL4 and
UFD1L), expressed CD4 in the absence or presence of Vpu, and
examined the localization of CD4 by immunofluorescence
microscopy (Fig. 3, A-L), sensitivity to Endo H (Fig. 3, P and
Q), and FACS analysis (Fig. 3, R and S). Immunofluorescence
microscopy showed that CD4 was predominantly at the plasma
membrane in the absence of Vpu (Fig. 3B). As expected,
expression of Vpu, which localized to the ER as well as
juxtanuclear structures corresponding to the trans-Golgi network
and endosomes (Fig. 3, E and M–O; Fig. S3, A–C), caused a
marked loss of CD4 staining in mock-treated cells (Fig. 3F).
Interestingly, in NPL4-depleted cells, both Vpu (Fig. 3I) and the
protected CD4 (Fig. 3J) co-localized on the ER, as evidenced by
co-staining for the ER-resident protein, calnexin (Fig. 3K).
Normally, newly-synthesized CD4 receives two N-linked high-
mannose oligosaccharide chains, only one of which acquires
complex carbohydrates upon transport through the Golgi complex
[16]. Treatment with Endo H removes one high-mannose chain,
whereas treatment with PNGase F removes both chains, as
detected by SDS-PAGE and immunoblot analysis of total CD4
(Fig. 3P, top panel; Fig. 3Q). The small amount of CD4 that
remained upon expression of Vpu in mock-treated cells was
completely sensitive to Endo H, indicating that it was localized to
the ER (Fig. 3P, middle panel; Fig. 3Q). This phenotype was not
due to a general impairment of protein maturation through the
biosynthetic pathway because acquisition of Endo H-resistance by
the transferrin receptor was not affected by expression of Vpu (Fig.
S3, D and E). Significantly, in NPL4-depleted, Vpu-expressing
cells, ,75% of CD4 remained sensitive to Endo H (Fig. 3P, lower
panel; Fig. 3Q), consistent with localization of the majority of CD4
to the ER. Finally, FACS analysis showed that depletion of NPL4
per se did not alter expression of CD4 at the cell surface in the
absence of Vpu (Fig. 3, R and S). However, in line with the
experiments described above, Vpu drastically reduced (,80%)
surface CD4 expression even in NPL4-depleted cells (Fig. 3, R and
S). Altogether, these results demonstrated that a large fraction of
CD4 remains in the ER in the presence of Vpu when targeting for
degradation is blocked. Therefore, Vpu mediates CD4 retention in
the ER in addition to degradation.
Binding of b-TrCP1/2 to Vpu Contributes to CD4
Retention in the ER
To dissect the mechanism by which Vpu causes CD4 retention
in the ER, we examined the effect of disrupting the Vpu-b-
TrCP1/2 interaction by either mutating serines 52 and 56 to
asparagine in Vpu [21,25] or depleting cells of both b-TrCP1 and
b-TrCP2 [22]. A quantitative measure of ER retention was
obtained by Endo H treatment in conjunction with immunoblot-
ting (Fig. 4, A and B) or pulse-chase analysis (Fig. 4, C and D).
Using these assays, we found that ,50% of CD4 was retained in
the ER upon disruption of the Vpu-b-TrCP1/2 interaction by
either method. Consistent with these observations, FACS analysis
showed that expression of Vpu-S52,56N, depletion of b-TrCP1/2,
or a combination of both, resulted in ,50% reduction of CD4
surface levels (Fig. 4, E and F). Comparison to the retention
observed upon NPL4 depletion (,75%) (Fig. 3, P–S) indicated
that binding of b-TrCP1/2 to Vpu contributes to CD4 retention
in the ER, but is probably not the only factor.
Lysine and Serine/Threonine Residues in the Cytosolic
Tail of CD4 Contribute to Ubiquitination, Degradation
and ER Retention
Binding of b-TrCP1/2 to Vpu could contribute to CD4
retention in the ER directly through assembly of a transport-
incompetent complex or indirectly through ubiquitination medi-
ated by the SCF
b-TrCP complex. To examine the role of
ubiquitination in ER retention and degradation, we mutated all
potential Ub-acceptor lysine residues to arginine (CD4-K-less) or
lysine, serine and threonine residues to arginine, alanine and
isoleucine, respectively (CD4-KST-less), in the cytosolic tail of
CD4 (Fig. 5A). None of these mutations affected the ability of CD4
to interact with Vpu-S52,56N, as determined by co-precipitation
analysis (Fig. 5B). Ubiquitination was assessed by co-expression of
untagged CD4 constructs with FLAG-tagged Ub in the absence or
presence of Vpu. Cell extracts were fully denatured prior to
immunoprecipitation with a conformation-independent antibody
to a luminal CD4 epitope and immunoblotting with an antibody
to the FLAG epitope (Fig. 5C). This protocol ensured that
ubiquitinated species corresponded to CD4 and not to associated
proteins. The amounts of ubiquitinated CD4 were normalized to
the amounts of remaining CD4 in each sample (Fig. 5, D and E).
We observed that expression of Vpu enhanced ubiquitination of
CD4 ,39-fold (Fig. 5, C and E). Mutation of all four cytosolic
lysines decreased but did not completely abolish CD4 ubiquitina-
tion (Fig. 5, C and E) and only slightly diminished degradation
(Fig. 5, C and D) induced by Vpu. Additional mutation of the
cytosolic serine and threonine residues abrogated virtually all
ubiquitination (Fig. 5, C and E) and degradation (Fig. 5, C and D)
induced by Vpu. These results indicated that targeting of CD4 for
degradation depends on ubiquitination of lysine and serine/
threonine residues in the cytosolic tail.
Endo H digestion analysis showed that the CD4-K-less and
CD4-KST-less mutants were normally exported from the ER in
the absence of Vpu (Fig. 5, F and G). Expression of Vpu, however,
resulted in retention of ,80% of the CD4-K-less mutant in the ER
(Fig. 5, F and G), similarly to wild-type CD4 (Fig. 3, P and Q).
Interestingly, the CD4-KST-less mutant was retained ,50% in
the ER (Fig. 5, F and G). This level of retention is similar to that
observed upon disruption of the Vpu-b-TrCP1/2 interaction
(Fig. 4, A and B), indicating that the contribution of this
Figure 2. Specific functions for each member of the VCP-UFD1L-NPL4 complex in Vpu-mediated CD4 degradation. (A) Domain
structure of mouse VCP, mouse UFD1L and rat NPL4 used in this study. (B, G, I) HeLa cells were transfected with plasmids encoding human CD4, Vpu
and wild-type VCP or mutant VCP constructs (VCP-DN, VCP-AA, VCP-QQ) (B), wild-type UFD1L or mutant UFD1L constructs (UFD1L-DUT3, UFD1L-
DUT6) (G), or wild-type NPL4 or mutant NPL4 constructs (NPL4-DUBD, NPL4-DZFD) (I). At 12 h after transfection, cells were labeled with
[
35S]methionine-cysteine for 2 min and chased for the indicated times at 37uC. (D) HeLa cells expressing human CD4 and Vpu were pulse-labeled as
described above and chased in normal (+ATP) or ATP-depleted (-ATP) medium. (B, D, G, I) Cell extracts were subjected to immunoprecipitation using
an antibody to the CD4 cytosolic tail. Immunoprecipitated proteins were analyzed by SDS-PAGE and fluorography. (C, E, H, J) Percentage of CD4 at
each chase time relative to CD4 at time 0 (100% control). (F) HeLa cells were transfected with plasmids encoding human CD4 and RGS-His-tagged
VCP-QQ, plus no Vpu (empty vector), wild-type Vpu or Vpu-S52,56N. At 12 h after transfection, cells were lysed and subjected to
immunoprecipitation with an antibody to the CD4 ectodomain. Co-precipitation of RGS-His-tagged VCP-QQ with CD4 in the presence of wild-
type Vpu was detected by immunoblotting with an antibody to the RGS-His epitope. (K) HeLa cells were treated without (mock) or with siRNAs to
VCP, UFD1L or NPL4. Cell extracts were prepared and subjected to immunoblotting with antibodies to VCP, UFD1L or NPL4.
doi:10.1371/journal.ppat.1000869.g002
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b-TrCP–
mediated ubiquitination of the CD4 cytosolic tail.
TMD Interactions Are the Main Determinant of ER
Retention of CD4 by Vpu
The fact that Vpu still retains ,50% of CD4 in the ER
independently of the interaction of Vpu with b-TrCP1/2 or the
ubiquitination of the CD4 cytosolic tail suggests an additional role
for the CD4-Vpu interaction in ER retention of CD4. This
interaction has been previously shown to depend on the cytosolic
domains of both CD4 and Vpu [20]. To test whether this particular
interaction accountedforthebulkofERretention,weexaminedthe
effect of deleting most of the cytosolic tail from CD4 (residues 426–
458) (CD4-Dcyto construct; Fig. 5A). This truncation should
eliminate interaction with Vpu and, consequently, all retention
and degradation determinants. As expected, CD4-Dcyto was not
degraded in the presence of Vpu (Fig. 6, A and B) [20]. Pulse-chase
experiments combined with Endo H digestion showed that CD4-
Dcyto completely exited the ER, albeit more slowly than full-length
CD4, in the absence of Vpu (Fig. 6, C and D). These results
indicated that the CD4 cytosolic tail has only a weak ER export
signal. Surprisingly, expression of Vpu resulted in ,80% retention
of CD4-Dcyto in the ER (Fig. 6, E and F). Similar results were
obtained with a CD4constructhavinga more radicaldeletion ofthe
cytosolic domain (residues 422–458) (Fig. 5A) (data not shown).
Therefore, interactions other than those between the cytosolic
domains must be the main determinants of Vpu-mediated retention
of CD4 in the ER. Since Vpu has a very short and variable luminal
domain (3–12 non-conserved amino acids; 4 in the HIV-1 NL4-3
variant used in this study), direct or indirect interactions at the level
of the TMDs mustbe the main determinant of the CD4 retention in
the ER mediated by Vpu. The fact that ER retention of CD4-Dcyto
by Vpu-S52,56N was greater (,75%) (Fig. 6, E and F) than that of
full-length CD4 (,50%) (Fig. 4, A and B) further supports the
occurrence of a weak ER export signal in the CD4 cytosolic tail.
These effects at the level of the ER were reflected in changes in
surface expression of CD4 analyzed by FACS (Fig. 6, G and H).
Thus, Vpu has an intrinsic ability to retain CD4 in the ER that is
independent of the cytosolic domain of CD4 and is likely mediated
by TMD interactions.
To assess more directly the importance of the Vpu TMD, we
replaced it with that of the G protein of vesicular stomatitis virus
(VSV-G), resulting in a chimera designated Vpu-VSV-G-TMD
(Fig. 7A). Co-precipitation experiments showed that Vpu-VSV-G-
TMD interacted with b-TrCP1 (Fig. 7B) and CD4 (Fig. 7C) to the
same extent as wild-type Vpu. However, this chimera largely failed
to promote CD4 degradation (Fig. 7, C and D). This observation is
in line with previous reports that substitutions of the Vpu or CD4
TMDs abrogate Vpu-induced CD4 degradation [48,49]. The
TMDs must therefore play a specific role in ERAD, perhaps in
allowing dislocation of CD4 from the ER membrane. Immuno-
fluorescence microscopy (Fig. 7, E–P) and Endo H digestion
analysis (Fig. 7, Q and R) showed that Vpu-VSV-G-TMD also
failed to prevent exit of the bulk of CD4 from the ER towards the
plasma membrane. Only a minor fraction of CD4 (,25%)
remained in the ER in the presence of Vpu-VSV-G-TMD (Fig. 7,
Q and R), presumably because of cytosolic domain interactions
with Vpu/b-TrCP1/2 and ensuing ubiquitination (Figs. 4 and 5).
Taken together, these results indicate that TMD interactions play
important roles in Vpu-dependent ER retention and degradation
of CD4.
A Strong ER Export Signal Overrides ER Retention of CD4
Mediated by Vpu
Unlike CD4, VSV-G has a strong ER export signal in its
cytosolic tail [50]. Substitution of the VSV-G cytosolic tail for the
CD4 cytosolic tail resulted in a chimeric protein (CD4-VSV-G-
cyto mutant; Fig. 8A) that was not degraded in the presence of
Vpu (Fig. 8, B and C), presumably because the VSV-G cytosolic
tail does not interact with Vpu and lacks degradation determi-
nants. Endo H digestion showed that, in contrast to CD4-Dcyto,
this chimera was efficiently transported out of the ER both in the
absence or presence of Vpu (Fig. 8, D and E). In addition, FACS
analysis showed that this chimera was expressed at the cell surface
very efficiently irrespective of the presence or absence of Vpu
(Fig. 8, F and G). Therefore, the VSV-G export signal is capable of
overriding ER retention of CD4 mediated by Vpu.
Discussion
Dual Functions of Vpu in ER Retention and ERAD
Targeting of CD4
The results of our study shed light on two aspects of Vpu
function that remained poorly understood: its ability to retain CD4
in the ER and to target CD4 to the ERAD pathway. The scheme
shown in Fig. 8H represents our view of how these aspects are
integrated. We think that Vpu first acts to retain CD4 in the ER
(Fig. 3) by virtue of TMD interactions (Figs. 6 and 7). The cytosolic
domain of Vpu then interacts with CD4 and recruits the SCF
b-
TrCP Ub ligase complex (Fig. 4) [21,22], which mediates the
addition of multiple Ub moieties to lysine [23,24] and serine/
threonine residues (Fig. 5) in the cytosolic tail of CD4.
Ubiquitination further contributes to CD4 retention in the ER,
and additionally marks CD4 for delivery to proteasomes (Fig. 5).
This delivery involves recruitment of the VCP-UFD1L-NPL4
complex through recognition by UFD1L of K48-linked poly-Ub
chains on the CD4 cytosolic tail (Figs. 1 and 2). The ATPase
activity of VCP then drives dislocation of CD4 from the ER
membrane into the cytosol (Fig. 2) [24] for eventual degradation in
proteasomes [17]. The multiple levels at which Vpu acts to
prevent export of CD4 from the ER underscore the importance of
ensuring complete suppression of CD4 for progression of the
infection.
The Mechanism of ER Retention
Our experiments show that a large fraction (,50-80%) of CD4
remains in the ER in the presence of Vpu when ERAD is blocked
labeled with a rabbit polyclonal antibody to Vpu (green channel; A, E, I), IgG2a mouse monoclonal antibody to CD4 (red channel; B, F, J) and IgG1
mouse monoclonal antibody to calnexin (blue channel; C, G, K). Stained cells were examined by confocal fluorescence microscopy. Bars: 10 mm. (M–O)
HeLa cells expressing Vpu were fixed and processed for immunoelectron microscopy as previously described [14]. Notice that enhanced nanogold
particles indicative of Vpu are mainly associated with the ER and nuclear envelope (NE). In contrast, untransfected cells show no enhanced nanogold,
confirming the specificity of the staining (Fig. S3). N: nucleus; PM: plasma membrane. Bars: 1 mm. (P) Total lysates from HeLa cells treated as in A–L
were digested with Endo H, PNGase F or left untreated before immunoblotting with an antibody to the CD4 ectodomain. CHO: N-linked carbohydrate
chain. (Q) Data are represented as mean 6 SEM from three independent experiments like that in P. (R) HeLa cells treated as in A–L were analyzed for
cell surface CD4 by FACS. (S) Bar graphs represent percentage of surface CD4 levels in cells expressing Vpu relative to CD4-surface levels in the
absence of Vpu (100%). Values are expressed as mean 6 SEM from three independent experiments.
doi:10.1371/journal.ppat.1000869.g003
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disruption of the Vpu-b-TrCP1/2 interaction (Fig. 4), or mutation
of lysine, serine and threonine residues in the cytosolic tail of CD4
(Fig. 5), in all cases in the absence of Env or any other inhibitor of
ER export. Furthermore, this retention is independent of the only
interaction between Vpu and CD4 reported to date, which
involves the cytosolic domains of both proteins [20]. Indeed,
deletion of the cytosolic tail of CD4 does not abrogate but rather
Figure 4. SCF
b-TrCP recruitment by Vpu is required for CD4 retention in the ER. (A) HeLa cells were treated without (mock) or with siRNAs to
b-TrCP1/2. Cells were then transfected with plasmids encoding human CD4 and no Vpu (empty vector), wild-type Vpu or Vpu-S52,56N. The
glycosylation state of CD4 was analyzed as described in the legend to Fig. 3P. (B) Data are represented as mean 6 SEM from three independent
experiments like that in A. (C) HeLa cells expressing human CD4 in the absence or presence of wild-type Vpu or Vpu-S52,56N were labeled with
[
35S]methionine-cysteine for 2 min and chased for the indicated times at 37uC. Cell extracts were subjected to immunoprecipitation with an antibody
to the CD4 cytosolic tail. Immunoprecipitated proteins were digested with Endo H or left untreated before analysis by SDS-PAGE and fluorography.
(D) Data from three independent experiments like that in C are represented as mean 6 SEM. (E) HeLa cells treated as in A were analyzed for cell
surface CD4 by FACS. (F) Bar graphs represent percentage of surface CD4 levels in cells expressing wild-type Vpu or Vpu-S52,56N relative to CD4-
surface levels in the absence of Vpu (100%). Values are expressed as mean 6 SEM from three independent experiments.
doi:10.1371/journal.ppat.1000869.g004
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Vpu or Vpu-S52,56N (Fig. 6). Since Vpu and cytosolic tail-less
CD4 only overlap at their TMDs, direct or indirect interactions at
this level must be the main determinant of ER retention. Indeed, a
Vpu mutant containing a heterologous TMD failed to retain CD4
in the ER (Fig. 7), further supporting a role of TMD interactions in
ER retention.
How could interaction with Vpu result in CD4 retention in the
ER? We envisaged that assembly with Vpu could either mask an
ER export signal on CD4, or confer on CD4 an intrinsic tendency
Figure 5. Requirement of lysine and serine/threonine residues in the cytosolic tail of CD4 for ubiquitination, degradation and ER
retention. (A) Sequence of the CD4 TMD and cytosolic tail with residues targeted for mutagenesis underlined. (B) HeLa cells were transfected with
plasmids encoding Vpu-S52,56N and no CD4 (empty vector), human wild-type CD4, CD4 with all four cytosolic lysine residues mutated to arginine
(CD4-K-less), or CD4 with all cytosolic lysine, serine and threonine residues mutated to arginine, alanine and isoleucine, respectively (CD4-KST-less). At
12 h after transfection, cells were lysed and subjected to immunoprecipitation with an antibody to the CD4 ectodomain and immunoblotting with an
antibody to Vpu. (C) HeLa cells were transfected with plasmids encoding no CD4 (empty vector), human wild-type CD4, CD4-K-less or CD4-KST-less
and FLAG-tagged Ub, plus or minus Vpu (1:0.5:1 ratio of CD4, Ub and Vpu, respectively). At 12 h after transfection, equivalent amounts of cell lysates
made under denaturing conditions were subjected to immunoprecipitation with a conformation-independent antibody to the CD4 ectodomain.
Ubiquitination of CD4 was detected by immunoblotting with a polyclonal antibody to the FLAG epitope. (D) CD4 levels in the presence of Vpu from C
were quantified by densitometry and expressed as percentage of the total amount of CD4 in the absence of Vpu (100% control). Data are represented
as the mean 6 SEM from three independent experiments. (E) Ubn-CD4 levels in the presence of Vpu from C were quantified by densitometry and
expressed as percentage of the total amount of Ubn-CD4 in the absence of Vpu (100% control). These values were normalized for the remaining CD4
in C (i.e., 1 for Ubn-CD4 in the absence of Vpu). Data are the mean 6 SEM from three independent experiments. (F) Cell lysates from HeLa cells
expressing human CD4, CD4-K-less or CD4-KST-less, plus or minus Vpu, were digested with Endo H, PNGase F or left untreated before
immunoblotting with an antibody to the CD4 ectodomain. The arrowhead indicates Endo H-sensitive species corresponding to the CD4-K-less
mutant in the presence of Vpu. (G) Data from three independent experiments such as that in F are represented as the mean 6 SEM.
doi:10.1371/journal.ppat.1000869.g005
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PLoS Pathogens | www.plospathogens.org 10 April 2010 | Volume 6 | Issue 4 | e1000869Figure 6. Deletion of CD4 cytosolic tail prevents degradation but not ER retention induced by Vpu. (A) HeLa cells were transfected with
plasmids encoding human CD4 or CD4-Dcyto together with no Vpu (empty vector), wild-type Vpu or Vpu-S52,56N. At 12 h after transfection, cell
extracts were prepared and subjected to immunoblotting with an antibody to the CD4 ectodomain. (B) CD4 levels in the presence of wild-type Vpu
Mechanism of CD4 Downregulation by Vpu
PLoS Pathogens | www.plospathogens.org 11 April 2010 | Volume 6 | Issue 4 | e1000869of Vpu to reside in the ER. Our analysis ruled the first possibility
unlikely, as CD4 has only a weak ER export signal in its cytosolic
tail (Fig. 6). Moreover, even this weak signal can wrest a small
amount of CD4 away from Vpu and out of the ER, as
demonstrated by the higher ER retention of cytosolic tail-less
CD4 relative to full-length CD4 in the presence of the Vpu-
S52,56N mutant (when neither CD4 construct is degraded) (Fig. 6).
Finally, replacement of the CD4 cytosolic tail by that of the VSV-
G protein, which has a strong ER export signal [50], completely
prevented ER retention of CD4 by Vpu (Fig. 8). Therefore, we
favor the second explanation of retention in trans, according to
which Vpu itself has ER retention information that is transmitted
to CD4 upon assembly. Indeed, our immunofluorescence and
immunoelectron microscopy analysis show that a large fraction of
Vpu localizes to the ER (Figs. 3 and S3), irrespective of the
presence or absence of CD4 (data not shown). CD4 may thus be
detained in the ER by forming a transport-incompetent complex
with Vpu.
The conveyance of ER retention information from Vpu to
CD4, however, does not account for the full extent of CD4
retention in the ER. SCF
b-TrCP-mediated ubiquitination on lysine
and serine/threonine residues in the CD4 cytosolic tail provides an
additional contribution to ER retention, as evidenced by the
higher degree of retention elicited by NPL4 depletion (Fig. 3)
relative to disruption of the Vpu-b-TrCP1/2 interaction (Fig. 4) or
mutation of Ub acceptor residues in the CD4 cytosolic tail (Fig. 5).
Recently, ubiquitination of a palmitoylation-deficient mutant of
the lipoprotein receptor-related protein 6 (LRP6) was also shown
to mediate ER retention of this protein [51]. The exact
mechanism by which ubiquitination can impart ER retention of
mutant LRP6 or CD4 in the presence of Vpu remains to be
elucidated. Therefore, Vpu retains CD4 in the ER, independently
of targeting to degradation, by the additive effects of two distinct
mechanisms: TMD-mediated conferral of ER residency (account-
ing for ,50% of the ER retention) and ubiquitination of the CD4
cytosolic tail (adding another ,25% to ER retention).
A Variant ERAD Pathway
In addition to retaining CD4 in the ER, Vpu targets newly-
synthesized CD4 for proteasomal degradation [5,16,17]. This
targeting has been proposed to be fundamentally distinct from
ERAD, mainly based on a study using yeast as a heterologous
expression system [23]. This study showed that the typical yeast
ERAD components, Hrd1p, Hrd3p and Ubc7p, are dispensable
for Vpu-induced CD4 degradation [23], a fact that our results
have confirmed for the human orthologs, HRD1, SEL1L and
UBC7, in human cells (Fig. 1). The participation of a non-ERAD
Ub ligase, SCF
b-TrCP, in Vpu-mediated CD4 degradation [21,22]
has further emphasized the distinctive nature of this process.
However, we find that the VCP-UFD1L-NPL4 complex, a key
component of the ERAD machinery, is involved in CD4
degradation by Vpu (Figs. 1 and 2). As previously shown for
other ERAD substrates [37,38,39,40], our results are consistent
with VCP-UFD1L-NPL4 mediating extraction of CD4 from the
ER membrane (Fig. 1). Vpu thus appears to bypass the early stages
of ERAD, including substrate recognition and ubiquitination by
ERAD machinery components, but joins in the later stages,
beginning with dislocation by the VCP-UFD1L-NPL4 complex.
We speculate that other components that act downstream of VCP-
UFD1L-NPL4 in typical ERAD [28] might also participate in
Vpu-induced CD4 degradation.
Over the past few years, it has become increasingly clear that
there is not a single ERAD pathway but several alternative routes
for targeting cellular proteins with defects in luminal (ERAD-L),
membrane (ERAD-M), and cytosolic domains (ERAD-C) [28].
Similarly, various herpesviruses downregulate class I molecules of
the major histocompatibility complex (MHC-I) from the ER by
engaging the ERAD machinery at different levels. For example,
the human cytomegalovirus (HCMV) immunoevasin, US11,
establishes TMD interactions with Derlin-1 that are required for
the ability of this viral protein to downregulate MHC-I [52]. In
contrast, another HCMV immunoevasin, US2, downregulates
MHC-I by a mechanism that is Derlin-1-independent [52] but
involves cytosolic domain interactions with signal peptide
peptidase [53]. The mK3 immunoevasin encoded by murine c-
herpesvirus 68 (MHV-68) exemplifies yet another variation on the
mechanisms used by herpesviruses to downregulate MHC-I [54].
Unlike US11 and US2, mK3 has intrinsic Ub ligase activity that
ubiquitinates newly-synthesized MHC-I, leading to its disposal by
the proteasome [55]. Importantly, all of these mechanisms
eventually merge at the level of the VCP-UFD1L-NPL4 complex
for delivery to the proteasome. In this context, Vpu-induced CD4
downregulation represents another adaptation to the use of the
same fundamental pathway for the proteasomal degradation of
ER-retained proteins.
The activities of Vpu are not limited to the ER, but extend to
other cellular compartments [10]. Indeed, Vpu has recently been
shown to downregulate the restriction factor BST-2/tetherin from
the cell surface [56,57]. In light of these findings, it will be of
interest to determine whether Vpu is capable of directly removing
pre-existing CD4 from the cell surface in addition to targeting
newly-synthesized CD4 to the ERAD pathway.
Involvement of Cytosolic Tail Serine/Threonine Residues
in CD4 Ubiquitination, ER Retention and ERAD Targeting
Mutation of all four lysines in the cytosolic tail of CD4 only
partially inhibited Vpu-induced CD4 ubiquitination and degra-
dation (Fig. 5). This led us to hypothesize that cytosolic tail
residues other than lysine could be additional targets for
ubiquitination. Previous studies showed that downregulation of
MHC-I by mK3 involved ubiquitination of not only lysine, but
also serine and threonine residues in the MHC-I cytosolic tail [55].
We tested whether this was also the case for Vpu-induced CD4
downregulation and found that more profound inhibition of CD4
ubiquitination and degradation could be achieved by mutation of
all lysine, serine and threonine residues in the CD4 cytosolic tail
were quantified by densitometry and expressed as percentage of the total amount of CD4 in the absence of Vpu (100% control). Data are represented
as the mean 6 SEM from three independent experiments. (C) HeLa cells expressing human CD4 or CD4-Dcyto in the absence of Vpu were labeled
with [
35S]methionine-cysteine for 2 min and chased for the indicated times at 37uC. Cell extracts were subjected to immunoprecipitation with an
antibody to the CD4 ectodomain. Immunoprecipitated proteins were digested with Endo H or left untreated before analysis by SDS-PAGE and
fluorography. The increased detection of both CD4 constructs from 0 to 30 min of chase is due to the development of a conformational epitope
recognized by this particular antibody. (D) Data from C are plotted as percentage of Endo H-resistant (Endo H
R) CD4 as a function of the chase time.
(E) Total cell lysates from HeLa cells treated as in A were digested with Endo H, PNGase F or left untreated before immunoblotting with an antibody
to the CD4 ectodomain. (F) Data from three independent experiments like that in E are represented as mean 6 SEM. (G) HeLa cells treated as in A
were analyzed for cell surface CD4 by FACS. (H) Bar graphs represent percentage of surface CD4 levels in cells expressing wild-type Vpu or Vpu-
S52,56N relative to CD4-surface levels in the absence of Vpu (100%). Values are expressed as mean 6 SEM from three independent experiments.
doi:10.1371/journal.ppat.1000869.g006
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tail of CD4 contributed to its retention in the ER mediated by Vpu
(Fig. 5). These observations are highly significant because Vpu,
unlike mK3, does not have intrinsic Ub ligase activity, indicating
that serine/threonine residues could be ubiquitinated by a cellular
enzyme. It will now be of interest to investigate whether this
modification is mediated by SCF
b-TrCP or another Ub ligase, and
whether other ERAD substrates undergo a similar modification.
Materials and Methods
Recombinant DNA Constructs
pcDNA3.1-FLAG-Ub was kindly provided by S. Ishikura
(NICHD, NIH). pFLAG-CMV2-human b-TrCP1 was obtained
from Y. Ben-Neriah (Hadassah Medical School, Hebrew Univer-
sity). pNLA-1 is a derivative of pNL4-3 [58], lacking the gag and pol
genes but expressing all other viral genes. pCMV-human CD4 [20]
and pcDNA3.1-codon-optimized Vpu(pcDNA3.1-Vphu) [41] were
used as templates for site-directed mutagenesis using a QuikChange
II kit (Stratagene, Cedar Creek, TX). pcDNA3.1 plasmids encoding
RGS-His-tagged mouse wild-type VCP, VCP-DN, VCP-AA and
VCP-QQ were previously reported [39,59]. Mouse wild-type
UFD1L, UFD1L-DUT3 (residues 215-307) and UFD1L-DUT6
(residues 1-214) cDNAs were amplified by PCR using pcDNA3.1-
FLAG-mouse UFD1L [60] as template and cloned as XhoI/
BamHI fragments into the pcDNA3.1/myc-His A vector (Invitro-
gen, Carlsbad, CA). To produce FLAG-tagged rat wild-type NPL4,
NPL4-DUBD (residues 96-608) and NPL4-DZFD (residues 1-579),
cDNAs were PCR-amplified from pFLAG-His-rat NPL4 [60] and
cloned into the pFLAG-CMV-6c vector (Sigma-Aldrich, Saint
Louis, MO) as EcoRI/BglII fragments. C-terminal FLAG-One-
STrEP-tagged CD4 was cloned as an EcoRI/BamHI fragment into
thepcDNA3.1/myc-HisAvector.pCMV-humanCD4andpEGFP-
N1-VSV-G [61] were used as templates in a sewing PCR strategy to
generate the CD4-VSV-G-cyto chimeric cDNA (human CD4: bp
1–1260; VSV-G: bp 1447–1536), which was cloned as an EcoRI/
NotI fragment into the pCI-Neo vector (Promega, Madison, WI). A
sewing PCR approach was also used to create a cDNA encoding
Vpu-VSV-G-TMD (Vpu: bp 1–12; VSV-G: bp 1393-1461; Vpu:
82–246), which was cloned into the pcDNA3.1/myc-His A vector as
a EcoRI/XhoI fragment. All mutagenesis and cloning products
were verified by DNA sequencing.
Antibodies
The following mouse monoclonal antibodies were used in this
study: 4B12 (Leica Microsystems, Bannockburn, IL), OKT4
(eBiosciences, San Diego, CA) or unconjugated and allophycocya-
nin (APC)-conjugated S3.5 (Caltag Laboratories, Burlingame, CA)
to human CD4; Ab-5 to actin, clone 37 to calnexin and clone 19 to
UFD1L (BD Biosciences, San Jose, CA); 58.13.3 to VCP (RDI
Research Diagnostics, Concord, MA); H68.4 to human transferrin
receptor (Zymed, San Francisco, CA); M2 to FLAG (Sigma-
Aldrich). A mouse polyclonal antibody to NPL4 was obtained from
Novus Biologicals (Littleton, CO). Rabbit polyclonal antibodies to
FLAG and myc were from Sigma-Aldrich and Cell Signaling
(Danvers, MA), respectively. Rabbit polyclonal antibodies to the
human CD4 cytosolic tail (residues 420 to 447) [17] and Vpu
(residues 32 to 81) [62] were previously described. Alexa Fluor 488-
conjugated donkey anti-rabbit IgG (H+L) was from Molecular
Probes (Eugene, OR). Alexa Fluor 594- or 647-conjugated donkey
anti-mouse IgG2a or IgG1, respectively, were from Invitrogen.
HRP-conjugated donkey anti-mouse IgG and donkey anti-rabbit
IgG were from Amersham Biosciences (Piscataway, NJ).
Cell Culture, Transfections and siRNA Treatment
HeLa cells (American Type Culture Collection, Manassas, VA)
were transiently transfected by using Lipofectamine 2000
(Invitrogen). Plasmids encoding human CD4 (pCMV-CD4) and
codon-optimized Vpu (pcDNA3.1-Vphu) were transfected at a 1:1
ratio. Vpu levels driven from this codon-optimized construct were
,3-fold higher than those driven from the proviral pNL4-3
construct (Fig. S4). However, similar levels of CD4 downregula-
tion were attained with amounts of codon-optimized Vpu that
were up to 16-fold lower (Fig. S4). ON-TARGETplus SMART-
pool siRNAs and siControl duplex siRNA (Dharmacon, Lafayette,
CO) at a final concentration of 100 nM were used to knockdown
expression of endogenous ERAD targets (including b-TrCP1/2)
and GAPDH, respectively (Table S1). Silencing was achieved by
double transfection of 0.56105 HeLa cells with Oligofectamine
(Invitrogen). Cells were analyzed 48 h after the second round of
transfection.
Immunoprecipitation and Immunoblotting
Cells were lysed in ice-cold lysis buffer (0.5% Triton X-100,
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA)
supplemented with the complete Mini protease inhibitor cocktail
(Roche Diagnostics, Indianapolis, IN). Equivalent amounts of cell
lysates were subjected to immunoprecipitation as described [63].
Immunoprecipitated proteins or whole cell lysates (10 mg) were
subjected to SDS-PAGE using the NuPAGE Bis-Tris Gel system
(Invitrogen) and immunoblotting as previously described [64].
Membrane bound horseradish peroxidase (HRP)-conjugated
antibodies were detected using the SuperSignal West Pico
Chemiluminescent Substrate from Thermo Scientific (Rockford,
IL). Data analysis was performed using the Image J software.
Pulse-Chase Analysis
Cells grown in 6-well plates were incubated for 30 min at 37uC
in methionine- and cysteine-free DMEM (Invitrogen), pulse-
Figure 7. The Vpu TMD is required for induction of both ER retention and degradation of CD4. (A) Amino acid sequence of the TMD and
cytosolic tail of wild-type Vpu and Vpu-VSV-G-TMD. (B) HeLa cells were transfected with plasmids encoding FLAG-tagged human b-TrCP1, plus no
Vpu (empty vector), wild-type Vpu, Vpu-S52,56N or Vpu-VSV-G-TMD. At 12 h after transfection, cells were lysed and subjected to
immunoprecipitation using an antibody to the FLAG epitope. Co-precipitation of the different Vpu variants with b-TrCP1 was detected by
immunoblotting with an antibody to Vpu. Notice that only phosphorylatable wild-type Vpu and Vpu-VSV-G-TMD co-precipitate with b-TrCP1. (C)
Detergent lysates from HeLa cells expressing human CD4 in the absence or presence of wild-type Vpu, Vpu-S52,56N or Vpu-VSV-G-TMD were
immunoprecipitated with an antibody to the CD4 ectodomain. Vpu co-precipitation with CD4 was detected as described in B. (D) CD4 levels in the
presence of wild-type Vpu or Vpu-VSV-G-TMD were quantified by densitometry and expressed as percentage of the total amount of CD4 in the
absence of Vpu (100% control). Values are the mean 6 SEM from three independent experiments. (E–P) HeLa cells were transfected with plasmids
encoding human CD4 and no Vpu (empty vector; E–H), wild-type Vpu (I–L) or Vpu-VSV-G-TMD (M–P). At 12 h after transfection, cells were fixed,
permeabilized and labeled with a rabbit polyclonal antibody to Vpu (green channel; E, I, M), IgG2a mouse monoclonal antibody to CD4 (red channel;
F, J, N) and IgG1 mouse monoclonal antibody to calnexin (blue channel; G, K, O). Stained cells were examined by confocal fluorescence microscopy.
Bars: 10 mm. (Q) Total lysates from HeLa cells treated as in E–P were digested with Endo H, PNGase F or left untreated before immunoblotting with an
antibody to the CD4 ectodomain. (R) Data are represented as mean 6 SEM from three independent experiments like that in Q.
doi:10.1371/journal.ppat.1000869.g007
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35S]methionine-cysteine (Express Pro-
tein Label; Perkin Elmer, Boston, MA) for 2 min at 37uC, and
chased in complete medium (DMEM supplemented with 10%
fetal bovine serum) supplemented with 5 mM L-methionine and
L-cysteine (Sigma-Aldrich). Cellular ATP levels were depleted
during the chase period using 20 mM 2-deoxy-D-glucose and
10 mM sodium azide (Sigma-Aldrich) in glucose-free DMEM
(Invitrogen). At each chase time, cells were extracted by incubation
in ice-cold lysis buffer (0.5% Triton X-100, 50 mM Tris-HCl
pH 7.5, 300 mM NaCl, 5 mM EDTA) supplemented with a
Figure 8. A strong ER export signal overrides ER retention of CD4 by Vpu. (A) Amino acid sequence of the TMD and cytosolic tail of wild-
type CD4 and CD4-VSV-G-cyto. (B, C) The effect of Vpu on human CD4, CD4-Dcyto or CD4-VSV-G-cyto was analyzed as described for Fig. 6, A and B.
(D, E) The carbohydrate processing of CD4 and CD4-VSV-G-cyto in the presence or absence of Vpu was analyzed as described for Fig. 6, E and F. (F, G)
HeLa cells expressing human CD4 or CD4-VSV-G-cyto, plus or minus Vpu, were analyzed for cell surface CD4 by FACS as described for Fig. 6, G and H.
(H) Model for the dual role of Vpu in ER retention and ERAD targeting of CD4. See Discussion for details.
doi:10.1371/journal.ppat.1000869.g008
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immunoprecipitation as described [63]. Immunoprecipitated
proteins were analyzed by SDS-PAGE and visualized by
fluorography on a Typhoon 9200 PhosphorImager (Amersham
Biosciences). Data analysis and quantification was performed using
the ImageQuant software.
Subcellular Fractionation
Cell fractionation and membrane protein extraction with
Na2CO3 were performed as previously described [65].
Microscopy
Indirect immunofluorescence staining of fixed, permeabilized
cells was performed as described [64]. Cells were examined with
an Olympus FluoView FV1000 laser scanning confocal unit
attached to an Olympus IX81 motorized inverted microscope as
previously described [66]. Immunoelectron microscopy was
performed as reported [14].
In Vivo Ubiquitination
Immunoprecipitation of CD4 under denaturing conditions was
performed as described [63]. Briefly, HeLa cells expressing FLAG-
or myc-tagged Ub were lysed in a denaturing lysis buffer (1% SDS,
50 mM Tris-HCl pH 7.4, 5 mM EDTA, 10 mM dithiothreitol,
15 U/ml DNase I, 10 mM a-iodoacetamide, 5 mM N-ethylma-
leimide) supplemented with the complete Mini protease inhibitor
cocktail. After heating samples for 10 min at 100uC, the
suspensions were diluted 10-fold in a non-denaturing lysis buffer
(1% Triton X-100, 50 mM Tris-HCl pH 7.5, 150 mM NaCl,
5 mM EDTA, 10 mM a-iodoacetamide, 5 mM N-ethylmalei-
mide) supplemented with the complete Mini protease inhibitor
cocktail. CD4 was immunoprecipitated using a conformation-
independent anti-CD4 antibody. Alternatively, FLAG-One-
STrEP-tagged CD4 was pulled-down using Strep-Tactin sephar-
ose (IBA, Go ¨ttingen?, Germany). Ubiquitinated CD4 was then
analyzed by immunoblotting with antibodies to the FLAG or myc
epitopes, respectively.
Endo H and PNGase F Digestion
Cell lysates made in 1% SDS, 0.1 M Tris-HCl pH 8 were
processed for Endo H and PNGase F digestion as previously
reported [67].
Fluorescence-activated Cell Sorting (FACS)
Non-permeabilized cells were stained with an APC-conjugated
antibody to the human CD4 ectodomain and prepared for FACS
analysis as described [13].
Accession Numbers
The HIV-1 Vpu and human CD4 clones used in this study
correspond to Swiss-Prot entries P05923 and P01730, respectively.
Supporting Information
Table S1 Cellular factors targeted in the siRNA screen.
Found at: doi:10.1371/journal.ppat.1000869.s001 (0.06 MB
DOC)
Figure S1 CD4 half-life is dramatically shortened by Vpu in a
VCP-dependent manner. (A, B) Determination of CD4 half-life.
(A) HeLa cells expressing human CD4 were pulse-labeled for
2 min with [
35S]methionine-cysteine and then chased for the
indicated times at 37uC. Cell extracts were subjected to
immunoprecipitation with an antibody to the CD4 cytosolic tail.
(B) Percentage of CD4 at each chase time relative to CD4 at time 0
(100% control). The half-life of CD4 determined from this
experiment was ,4.8 h. (C, D) Phosphorylation of Vpu is essential
for CD4 degradation. (C) HeLa cells were transfected with
plasmids encoding human CD4 and no Vpu (empty-vector), wild-
type Vpu or the non-phosphorylatable Vpu-S52,56N. At 12 h
after transfection, cell extracts from cells treated as in A were
subjected to immunoprecipitation with antibodies to the CD4
cytosolic tail and Vpu. (D) Percentage of CD4 at each chase time
relative to CD4 at time 0 (100% control). (E, F) Analysis of CD4
stability in VCP-depleted cells expressing Vpu. (E) HeLa cells were
treated without (mock) or with siRNAs to VCP. Cells were then
transfected with plasmids encoding human CD4 and Vpu. At 12 h
after transfection, cells were treated as in A followed by
immunoprecipitation with an antibody to the CD4 cytosolic tail.
(F) Percentage of CD4 at each chase time relative to CD4 at time 0
(100% control). In all experiments, immunoprecipitated species
were analyzed by SDS-PAGE and fluorography.
Found at: doi:10.1371/journal.ppat.1000869.s002 (0.35 MB TIF)
Figure S2 CD4 ubiquitination depends on Vpu phosphoserines
52 and 56. (A) HeLa cells were transfected with plasmids encoding
FLAG-One-STrEP-tagged human CD4 and myc-tagged Ub, plus
no Vpu (empty vector), wild-type Vpu or Vpu-S52,56N (1:0.5:1
ratio of CD4, Ub and Vpu, respectively). At 12 h after
transfection, equivalent amounts of cell lysates made under
denaturing conditions were subjected to pull-down with Strep-
Tactin-Sepharose. Ubiquitination of CD4 was detected by
immunoblotting with a polyclonal antibody to the myc epitope.
(B) CD4 levels in the presence of wild-type Vpu or Vpu-S52,56N
from A were quantified by densitometry and expressed as
percentage of the total amount of CD4 in the absence of Vpu
(100% control). Data are represented as the mean 6 SEM from
three independent experiments. (C) Ubn-CD4 levels in the
presence of wild-type Vpu or Vpu-S52,56N from A were
quantified by densitometry and expressed as percentage of the
total amount of Ubn-CD4 in the absence of Vpu (100% control).
These values were normalized for the remaining CD4 in A (i.e.,1
for Ubn-CD4 in the absence of Vpu). Data are the mean 6 SEM
from three independent experiments.
Found at: doi:10.1371/journal.ppat.1000869.s003 (0.39 MB TIF)
Figure S3 ER localization of Vpu and lack of effect on
transferrin receptor stability, maturation and transport. (A-C)
Specificity of Vpu localization to the ER. HeLa cells expressing
Vpu were fixed and processed for immunoelectron microscopy. A
Vpu-transfected and a Vpu-untransfected cell stained with an
antibody to Vpu and a nanogold-conjugated secondary antibody
were imaged in the same field of view. Notice the staining of the
ER cisternae and the nuclear envelope in the transfected cell and
the total absence of staining in the untransfected cell. N: nucleus;
PM: plasma membrane. Bars: 1 mm. (D, E) Transferrin receptor
(TfnR) stability, maturation and transport are not affected by Vpu
expression. (D) Cell lysates from HeLa cells were digested with
Endo H, PNGase F or left untreated before immunoblotting with
an antibody to the TfnR cytosolic tail. (E) Data are represented as
mean 6 SEM from three independent experiments like that in D.
Found at: doi:10.1371/journal.ppat.1000869.s004 (0.63 MB TIF)
Figure S4 Expression of codon-optimized Vpu at levels
comparable to those from proviral DNA are fully effective at
downregulating CD4. (A) Codon-optimized Vpu is expressed at
,3-fold higher levels than Vpu expressed from proviral DNA.
HeLa cells were transfected with 2.5 mg of the proviral pNL4-3
(,14.8 kb) or pNLA-1 (,10.7 kb) plasmids, or with varying
amounts of the pcDNA3.1-codon-optimized Vpu (pcDNA3.1-
Mechanism of CD4 Downregulation by Vpu
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dilution. Total amounts of transfected DNA were kept constant in
all samples by compensation with empty-vector DNA. At 12 h
after transfection, cell extracts were subjected to immunoblotting
with antibodies to Vpu and actin (used as a loading control). A 1:1
dilution of pNL4-3 was found to yield Vpu expression levels
equivalent to a 1:8 dilution of pcDNA3.1-Vphu. Correcting for the
different sizes of these plasmids (i.e., comparing equivalent molar
amounts), the Vpu expression level yielded by pcDNA3.1-Vphu
was ,3-fold higher than that from pNL4-3. (B–E) Similar
decreases of both cell surface and total CD4 levels are attained
with 1:1 to 1:16 dilutions of plasmid encoding Vphu. (B) HeLa
cells were transfected with 2.5 mg of a construct encoding human
CD4 and several dilutions of the pcDNA3.1-Vphu or pcDNA3.1-
Vphu-S52,56N (i.e., 2.5 mg=1:1 dilution). At 12 h after transfec-
tion, cell lysates were subjected to immunoblotting with antibodies
to CD4, Vpu and actin (used as a loading control). Notice that
increasing amounts of expressed Vphu-S52,56N did not affect
CD4 expression and stability. (C) CD4 levels in the presence of
Vphu were quantified by densitometry and expressed as
percentage of the total amount of CD4 in the absence of Vphu
(100% control). (D) HeLa cells transfected with 2.5 mg of a plasmid
encoding human CD4 and different amounts of pcDNA3.1-Vphu
(i.e., 2.5 mg=1:1 dilution) were analyzed for cell surface CD4 by
FACS. (E) Bar graphs represent percentage of surface CD4 levels
in cells expressing Vphu relative to CD4-surface levels in the
absence of Vphu (100%). Values are expressed as mean 6 SEM
from three independent experiments.
Found at: doi:10.1371/journal.ppat.1000869.s005 (1.05 MB TIF)
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